|
INMB | Inmune Bio, Inc. |
|
|
INMB | Inmune Bio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.57 |
| Leverage | 19.72% |
| Market Cap | $ 165.4m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -40.7m |
| Margin | -7507.83% |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patients innate immune system to treat cancer, Alzheimers disease, and nonalcoholic steatohepatitis. The company is headquartered in La Jolla, California.